title: New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
authors.affiliation: Johannes Gutenberg University Mainz, Mainz, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Weber
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000068338:Everolimus; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D015282:Octreotide / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013514:Surgical Procedures, Operative
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007166:Immunosuppressive Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D000068338:Everolimus; D015282:Octreotide; D020123:Sirolimus